Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion
TheFly reported on January 13 that Leerink Partners lowered the price target on KURA to $20 from $25 and maintained an Outperform rating.
Kura Oncology Inc. (KURA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 8,617,162 | $89,532,313 | 3.01% | |
| 2. | Suvretta Capital Management Aaron Cowen | 8,575,422 | $89,098,635 | +6% | 1.83% |
| 3. | Armistice Capital Steven Boyd | 4,936,000 | $51,285,040 | +6% | 0.61% |
| 4. | AQR Capital Management Cliff Asness | 3,062,212 | $31,816,384 | +37% | 0.02% |
| 5. | Prosight Capital Lawrence Hawkins | 2,529,600 | $26,282,544 | -9% | 5.43% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.20 | 50,000 | $410,145.00 | 100,968 | 2025-09-08 | Filing | |
| $6.64 | 13,494 | $89,623.10 | 50,968 | 2025-08-13 | Filing | |
| $5.85 | 36,506 | $213,578.35 | 37,474 | 2025-08-12 | Filing | |
| $11.50 | 50,000 | $575,000.00 | 139,557 | 2023-06-16 | Filing | |
| $13.16 | 83,540 | $1,099,386.40 | 4,408,097 | 2018-12-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.46 | 1,572 | $13,300.22 | 183,275 | 2026-01-27 | Filing | |
| $8.46 | 4,842 | $40,966.23 | 184,847 | 2026-01-27 | Filing | |
| $8.46 | 1,813 | $15,339.25 | 153,560 | 2026-01-27 | Filing | |
| $8.46 | 1,341 | $11,345.80 | 267,274 | 2026-01-27 | Filing | |
| $8.46 | 951 | $8,046.13 | 268,615 | 2026-01-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,010,793 | $93,622,139 | 0% | |
| 2. | 5,507,627 | $57,224,245 | 0% | |
| 3. | 4,931,090 | $51,234,025 | 0% | |
| 4. | 2,028,618 | $21,081,811 | 0% | |
| 5. | 2,022,333 | $21,012,040 | 0.08% |
News See All
20 Best Biotech Stocks Under $20 to Buy Now
The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.
7 Stocks That Were on Jim Cramer’s Radar
“After an agonizing period where Wall Street decided it was done with one of the greatest growth stories in history, artificial intelligence and everything attached to it, today, we got a reprieve, ...
Jim Cramer’s Latest Insights on These 13 Stocks
“We're starting to wind down for the year, but there's still some big reports coming from industries that are real battlegrounds. Take the home builders...
Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval
Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2025 Earnings Call Transcript
Operator: Good day, everybody. My name is Danny, and I will be your conference operator today. At this time, I would like to welcome you to the Kura Oncology Third Quarter 2025 Conference Call.
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript
Operator: Hello, and welcome, everyone, joining today's Second Quarter 2025 Kura Oncology, Inc. Financial Results Conference Call. [Operator Instructions] Please note this call is being recorded.
FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s Ziftomenib
The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ziftomenib, an investigational treatment pursued by Kura Oncology, Inc.
Hedge Fund Resource Center